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Promising investigational drug candidates in phase I and phase II clinical trials for 
mesothelioma 
Abstract 
 
Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting 
the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and 
current treatments remain ineffective, leading to poor prognosis. Within this article potential 
targets to improve the quality of life of the patients and assessment of further avenues for 
research are discussed. 
 
Areas covered: This review highlights emerging therapies currently under investigation for 
malignant mesothelioma with a specific focus on phase I and phase II clinical trials. Three 
main areas are discussed: immunotherapy (immune checkpoint blockade and cancer vaccines, 
among others), multitargeted therapy (such as targeting pro-angiogenic genes) and gene 
therapy (such as suicide gene therapy). For each, clinical trials are described to detail the 
current or past investigations at phase I and II. 
 
Expert opinion: The approach of applying existing treatments from other cancers does not 
show any significant benefit, with the most promising outcome being an increase in survival 
of 2.7 months following combination of chemotherapy with bevacizumab. It is our opinion 
that the hypoxic microenvironment, the role of the stroma, and the metabolic status of 
mesothelioma should all be assessed and characterised to aid in the development of new 
treatments to improve patient outcomes. 
 
Keywords: Malignant mesothelioma, immunotherapy, targeted therapy and gene therapy  
Highlights box 
 Since the success of immune checkpoint inhibitors and cancer vaccines approved 
by the FDA for the treatment of cancers such as melanoma, immunotherapy may be 
evaluated as a third-line therapy for cancer treatment after conventional treatments 
and targeted agents.  
 Mesothelin is one of the main targets in immunotherapeutic approaches but the 
efficacy of this strategy is still poor.  
 CTLA-4 and PD1/L1 blockage are widely investigated in numerous clinical trials 
as single or combined therapy in mesothelioma patients but the outcome is still 
unsatisfactory  
 Main targeted therapies against EGFR and VEGFA/VEGFR showed no clinical 
activity in mesothelioma patients and only slightly promising results have been 
shown in patients treated with bevacizumab in combination with chemotherapy.  
 It is our belief that to improve current therapies the role of the hypoxic 
microenvironment and influence of the stroma in chemoresistance should be further 
characterised, in addition to uncovering the extent of metabolic reprogramming that 
occurs in tumours cells. 
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1. Introduction  
 
Malignant mesothelioma (MM) is a lethal and rare malignancy arising from surface 
mesothelial cells lining cavities such as pleura (malignant pleural mesothelioma, MPM, 
approximately 80% of cases), peritoneum (approximately 20% of cases) whilst less than 1% 
of cases occur in the pericardium and tunica vaginalis [1, 2]_ENREF_2. The major common 
risk factor for MM is asbestos exposure but radiation and simian virus 40 (SV40) have also 
been implicated as additional risk factors for MM [3]. Recently, it has been reported that 
BRCA1 associated protein-1 (BAP1) mutation could be a genetic predisposition to MM [4]. 
MM is characterised by a long latency period (20-40 years) before the symptoms occur. The 
symptoms themselves are non-specific, which makes this tumour difficult to diagnose and the 
disease itself has a poor prognosis; the median survival rate is less than twelve months [5] 
and only 10-20% of cases present life expectancy of 5-years [6]. The worldwide incidence 
rate is increasing and a peak is expected between 2015-2030. A study on mesothelioma 
frequency between 1994-2008 reported a global average of 14,200 cases each year [7]. The 
USA, UK, Australia and Italy all report high incidence rates. In industrialized countries, 
where asbestos is used illegally, the incidence frequency is expected to increase, thus 
affecting the global incidence [8]. There is generally a lack of curative treatments for MM 
patients. Systemic treatment in the form of chemotherapy, radiotherapy and targeted therapy 
are options as single treatment or in combination in a multimodality regimen [8]. Surgery is 
debatable and is recommended only in patients with early stage disease and in a good general 
health. A number of novel therapeutic drugs are under investigation, and may provide further 
treatment options for MM in the future. In this review, we will summarise current clinical 
trials and highlight promising agents, giving an overall opinion from a translational research 
team. 
  
2. Body  
 
There are 256 clinical trials for MM currently reported in ClinicalTrials.gov, including 
recruiting, completed, active and terminated studies as single intervention or in combination 
modality. The main categories of agents investigated include immunotherapeutics, gene 
therapy, and multiple targeted therapies.  Different approaches will be discussed in turn 
throughout this manuscript, in addition to describing phase I and phase II trials for them. 
 
 
2.1 Immunotherapy 
 
Recently, immunotherapy, including active and passive therapeutic strategies has acquired a 
significant interest in the field of cancer treatment. Active strategies utilize tumour-specific 
antigens to trigger a direct immune system response such as cancer vaccines [9]. Passive 
approaches use an activated immune cell effector component such as immunomodulators 
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(including cytokines) and tumour-specific antibodies to target tumour antigens without direct 
stimulation of the immune system [10], whilst adoptive cellular therapy aims to administer 
genetically modified immune cells directly to patients [11]. For decades immunotherapy has 
reported clinical failures but recently the development of new molecules such as immune 
checkpoint inhibitors have shown promising results, leading to the approval of immune 
checkpoint inhibitors for the treatment of melanoma. Cytotoxic T-lymphocyte antigen 4 
(CTLA-4; CD152) is a key immune checkpoint and serves to downregulate immune 
responses, as does programmed death-1/programmed death ligand-1 (PD-1/PDL-1). 
Antibodies such as ipilimumab and nivolumab have been developed against CTLA-4 and PD-
1 respectively and were approved for the treatment of melanoma in 2011 and 2014 
respectively [9]. The most common use of immunotherapy is as part of combination therapy 
with other conventional and non-conventional approaches which aim to achieve enhanced 
efficacy with a diminished toxic effect, thus modulating a durable and adaptable cancer 
control response. Preclinical studies suggest a potential for synergistic effects on tumour 
response and overall survival in multimodality treatment with agents that target different 
immune checkpoints [12]. However, combination immunotherapy against multiple 
checkpoints has also demonstrated a high rate of side-effects, such as one study combining 
nivolumab and ipilimumab for the treatment of melanoma which showed side-effects at grade 
three or four in 55% of patients [13]. At present, immunotherapy typically evaluated as a 
third-line for cancer therapy after conventional treatments and targeted agents. 
 
Active Immunotherapy  
 
2.1.1 Cancer Vaccines 
 
The main aim of cancer vaccination is to educate immune system to recognise cancer cells, 
which exhibit specific tumour antigens, thereby restoring or promoting the ability of the 
immune system, mainly by CD8+ cytotoxic T cell activation, to fight cancer cells [14]. 
Several subcategories of vaccines have been developed, detailed below in the subsequent 
sections. 
 
2.1.2 Dendritic-Cell-Based Vaccines  
 
A strategy in the use of tumour vaccines is dendritic cells (DCs) loaded with tumour-
associated antigens. DCs are a heterogeneous population of antigen-presenting cells (APCs) 
and are specialized in processing proteins which leads to the subsequent presentation of 
antigens. Production of autologous DCs is carried out through ex vivo differentiation from 
peripheral blood precursors, followed by maturation of DCs to activate them [15]. Before 
being injected in the patients DCs are loaded with tumour lysates derived from patients either 
via viral infection or grown in media containing antigenic peptides [16]. Upon infusion into 
the patient, the activated DCs generate anti-tumour T-cell responses due to CD4+ T cells 
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activating CD8+ effector T-cells (Fig 1). In April 2010, the FDA approved Sipuleucel-T 
(PROVENGE; Dendreon) as the first therapeutic cancer vaccine for use in patients who have 
metastatic castration-resistant prostate cancer [17]. The success of this vaccine is related to 
the increase of overall survival, although the disease progression was unchanged, giving an 
alternative to patients with prostate [18]. However, ex vivo therapies such as PROVENGE 
had a limited practical use in other cancer types and produced an immune response with 
limited scope [19]. 
 
2.1.3 Peptide or Protein-Based Vaccines 
 
 
Peptide/protein-based vaccines work on the principle of stimulating CD8+ T cells to promote 
an anti-tumour effect, and consist of five broad categories:  mutated antigens expressed only 
by the tumours; overexpressed normal self-antigens; oncofoetal antigens which are present in 
foetal tissues as well as some adult tumours; differentiation or lineage antigens; and cancer-
testis antigens [20, 21, 22] (Fig 2). Among these, an interesting target is Wilms tumour gene 
(WT1) protein, which is highly expressed in various tumours, including mesothelioma and is 
associated with oncogenic function, providing  a strong rationale to consider WT1 as an 
attractive target for cancer immunotherapy [23]. An additional common target is mesothelin, 
a cell-surface antigen associated with tumour invasion, which is highly expressed in several 
solid tumours such as mesothelioma and has been targeted in immunotherapy approaches due 
to the fact that its expression is low in normal mesothelial cells. Cancer vaccines developed 
against mesothelin use a live attenuated Listeria monocytogenes-expressing mesothelin 
(CRS-207, JNJ-64041757). Numerous antigens with promising potential are under 
investigation in few cancers [24]. 5T4 vaccine (TroVax®) is targets an oncofoetal antigen 
called 5T4 which is inserted in a highly attenuated modified vaccinia ankara (MVA) virus. 
5T4 is upregulated in cancer with a limited expression in normal tissue and is associated with 
epithelial mesenchymal transition (EMT), contributing to metastasis of epithelial cancers 
[24]. Thus, this represents an interesting target for therapeutic development. 
 
2.1.4 Phase I Clinical Trials 
 
A preliminary study on murine malignant mesothelioma model showed that immunotherapy 
using tumour lysate–pulsed dendritic cells controlled MM outgrowth [25]. Following this a 
phase I study investigated the safety and immunological response after the administration of 
tumour lysate-pulsed dendritic cells in MPM patients. The results showed a well-tolerated 
profile, with the treatment inducing an immunological response to tumour cells in MPM 
patients (NCT00280982) [26]. Further, to investigate whether the combination of low-dose 
cyclophosphamide with autologous tumour lysate–pulsed dendritic cells was advantageous 
compared to monotherapy the effect of this combination on the suppressive function of 
regulatory T cells was assessed in 10 MPM patients. This approach demonstrated disease 
control and a well-tolerated profile (NCT01241682) [27]. 
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Another pilot study was designed to assess the safety profile and efficacy of tumour cell 
vaccines in combination with the chemotherapeutic compound cyclophosphamide and the 
anti-inflammatory drug celecoxib in patients with mesothelioma. The study has been 
completed and 10 patients have been enrolled but the data are not available yet 
(NCT01143545). An additional pilot study investigated the safety and immunogenicity 
profile of a WT1 vaccine in patients with thoracic neoplasms (mesothelioma and non-small 
cell lung cancer (NSCLC)) expressing WT1 [28]. Each vaccine dose was prepared by mixing 
equal volumes of adjuvant Montandine 51 with 200 µg each of four different peptide 
sequences known to bind MHC molecules and stimulate T cell responses [28]. 200 µg was 
chosen as it is a known safe and active concentration. Injection sites were pre-stimulated with 
sargramostim (GM-CSF) and vaccines were administered subcutaneously [28]. The immune 
response was stimulated in most of the patients, showing the ability of T cells to exert a 
cytotoxic effect against WT-1 positive cells. Therefore, a randomized II phase trial has been 
planned [28]. Phase I clinical trials have been recently completed or are still ongoing testing 
the safety of WT1-based vaccines (NCT00398138) which evaluate WT1 vaccination in 
conjunction with conventional chemotherapy (NCT02649829). The outcome of completed 
studies showed the vaccination promoted a tumour-specific immunity (both cellular and 
humoral) and was safe but a clinical response was not observed [29]. A phase I study tested 
CRS-207 (vaccine targeting mesothelin which is widely expressed on cancer cells) with 
chemotherapy in 38 patients. The clinical outcome showed that CRS-207 was well-tolerated 
and in combination with pemetrexed and cisplatin showed an anti-tumour activity with 59% 
of patients achieving an objective partial response and median progression free survival 
(PFS) of 8.5 months (NCT01675765) [30]. 
 
2.1.5 Phase II Clinical Trials 
 
A pilot study investigated the clinical effects of cyclophosphamide in combination with 
autologous or allogeneic tumour cell vaccines to treat patients with various advanced cancers 
including mesothelioma (NCT00002475). An ongoing phase II study is evaluating treatment 
with the WT-1 peptide vaccine in combination with Montanide/GM-CSF (granulocyte-
macrophage colony-stimulating factor) versus Montanide/GM-CSF alone in patients with 
MPM who have completed multimodality therapy (NCT01265433).  
 
Table 1: Phase I and II clinical trials for active immunotherapeutic approaches. 
 
ClinicalTrials.gov 
Identifier 
Phase Treatment 
Number of 
Patients 
NCT00280982 I 
Autologous dendritic 
cells 
10 
NCT01241682 I Autologous dendritic 
cells + low-dose 
10 
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cyclophosphamide 
NCT01143545 I 
Tumour cell vaccine 
in combination with 
cyclophosphamide  
and the anti-
inflammatory drug 
celecoxib 
10 
NCT00398138 I 
Wilms’ tumour-1 
(WT-1) vaccine, with 
injection sites being 
pre-stimulated by 
sargramostim (GM-
CSF) 
22 
NCT02649829 I/II 
Autologous dendritic 
cells loaded with WT-
1 antigen in 
conjunction with 
conventional 
chemotherapy 
Currently 
recruiting 
NCT01675765 I 
Cancer vaccine CRS-
207 (attenuated 
Listeria 
monocytogenes) with 
or without 
cyclophosphamide 
60 
NCT00002475 II 
Cyclophosphamide in 
combination with 
tumour cell vaccine 
40 
NCT01265433 II 
Either non-specific 
immunotherapy 
(montanide and 
sargramostim) or WT-
1 vaccine, montanide 
and sargramostim 
31 
 
 
Passive Immunotherapy  
 
2.1.6 Antibody-Based Therapies 
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One extensively investigated approach to overcome the toxicity of currently-used 
chemotherapies is the use of monoclonal antibodies (mAbs), which have the ability to 
precisely target malignant cells overexpressing specific surface antigens [31] (Fig 3A) . 
Rituximab (anti-CD20 mAb) is the first approved mAb for the treatment of cancer, raising 
the interest in the development of a number of actively pursued antibody (Ab)-based 
technologies, including immunotoxins, radioimmuno-
therapeutics, http://topics.sciencedirect.com/topics/page/Antibody-drug_conjugate and 
immunoliposomes [32].  
The main antibodies tested in clinical trials target mesothelin such as immunotoxins and 
chimeric antimesothelin antibodies (i.e. amatuximab) [33]. Antimesothelin immunotoxin 
SS1(dsFv)PE38 (SS1P) is a recombinant molecule with a murine antimesothelin variable 
antibody fragment (Fv) linked to PE38, a truncated portion of Pseudomonas exotoxin A. In 
preclinical models, SS1P reduced  mesothelin-expressing tumors, both alone and in 
combination  with chemotherapy and radiation therapy [34]. Amatuximab (MORAb-009) is a 
chimeric monoclonal antibody with a high affinity for human mesothelin (KD = 1.5 nM) [33, 
35]. Preclinical studies showed that amatuximab induces cell-mediated cytotoxicity in tumour 
cells expressing mesothelin [36]. Moreover, using toxicological analyses it has been 
demonstrated that amatuximab did not cause any adverse effects in mouse models [36]. 
GC1008 is a human anti-TGFβ monoclonal antibody that counteracts all isoforms of TGFβ 
thereby preventing tumour growth and metastasis [37, 38]_ENREF_31 . Preclinical data of 
TGFβ blockade in animal models of MPM and in human MPM cell lines suggest that TGFβ 
inhibitors can be effective therapeutic agents. In addition, high levels of TGFβ were found in 
rat and murine MPM cells as well as in tumours and in pleural effusions of MPM patients 
[39]. However, cost limitations, inadequate pharmacokinetics and tissue accessibility all 
contribute to the need for further investigation and improvement of this approach [40]. 
Anetumab ravtansine (BAY 94-9343) is another antibody under investigation in MPM 
patients overexpressing mesothelin. An in vitro study demonstrated that anetumab exerts 
potent and selective cytotoxicity against mesothelin-expressing cells [41]. A model study 
reported that anetumab interacts with mesothelin-positive tumours and inhibits tumour 
growth in xenograft models [41]. 
 
2.1.7 Cytokine-Based Therapy  
Cytokine-based immunotherapy aims to stimulate a cytotoxic immune response by providing 
rapid protection from antigens, which involves stimulation of non-specific natural  killer cells 
or highly specific cells such as cytotoxic T cells or Tumour Infiltrating Lymphocytes [42] 
(Fig 3B). Interleukin-2 (IL-2) is the first cytokine successfully used in clinical therapy but a 
small proportion of types of cancers can benefit from this approach and a complete clinical 
response occurs rarely [43]. Among immunotherapeutic cytokines investigated as potential 
treatments are interferons (α, β, γ), which lead to an immune response with a significant toxic 
effect against tumour cells [42]. In MPM, INFγ may contribute to a direct cytotoxic effect on 
mesothelial cells and stimulate NK and macrophages [44] .  
 
2.1.8 Phase I Clinical Trials 
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A phase I trial of SS1P (which exerts its effects via targeting of mesothelin and Pseudomonas 
exotoxin A) aimed to verify the side effects and best dose of this immunotoxin approach in 
treating patients with recurrent unresectable advanced solid tumours, including MPM 
(NCT00066651) [45]. 24 patients with different cancer types (9 with pleural mesothelioma, 5 
with peritoneal mesothelioma and 2 with pleural-peritoneal mesothelioma) were enrolled and 
the clinical outcome of this single therapy presented a well-tolerated profile up to 25 μg/kg/d 
×10 and exhibited a modest clinical activity, with 75% of patients exhibiting immunogenicity 
and 21% receiving a second cycle. One patient had a partial response, twelve had stable 
disease, and eleven had progressive disease [45]. Another clinical trial evaluated the safety 
and tumour response of SS1P in combination with pemetrexed and cisplatin in 24 patients 
with advanced MPM. SS1P given with pemetrexed and cisplatin had a safe and well tolerated 
clinical profile and showed significant antitumor activity with a partial response in 60% of 
patients (NCT01445392) [46]. A phase 1 study was conducted to assess the safest doses of 
amatuximab in patients with mesothelin-positive cancers (pancreatic, ovarian, mesothelioma 
and lung) (NCT00325494). Amatuximab exhibited a well-tolerated profile and the maximum 
tolerated dose (MTD) was chosen at 200 mg/m
2
 [47]. Another study investigated the dose-
limiting toxicity and estimated MTD involving 17 patients with mesothelin-positive cancer, 
including mesothelioma patients (NCT01018784). Amatixumab was well-tolerated and MTD 
was determined to be 200 mg/m
2
 in agreement with the study mentioned above [48]. A 
completed study investigating treatment with INF-α combined with cisplatin, surgery and 
radiotherapy in 6 MPM patients has also been performed, though results are not yet published 
(NCT00003263). 
 
2.1.9 Phase II Clinical Trials 
 
An open-label multicentre clinical trial investigated amatuximab plus pemetrexed and 
cisplatin for the treatment of 89 MPM patients. PFS and overall response (OR) were the 
endpoints for this study (NCT00738582) [49]. Due to amatuximab demonstrating a 
favourable safety profile, exploration in other mesothelin-expressing cancers may be 
justified. A Phase II investigation of GC1008 to assess the overall safety and effectiveness in 
13 patients with MPM has also been performed, which demonstrated that the drug was 
generally well-tolerated in MPM patients (NCT01112293). However, partial or complete 
radiographic responses were not achieved and stable disease was observed in only 3 subjects. 
Patients who produced anti-TGFβ antibodies had increased median overall survival (OS) (15 
vs 7.5 months, p < 0.03) [39]. 
 
2.1.10 Adoptive T Cell Therapy 
 
Adoptive immunotherapy uses genetically enhanced T cells to trigger a potent and tumour-
specific immune effect that affects small or large tumour burdens. The advantage of this 
approach is that it in theory avoids side effects and toxicities associated with standard 
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approaches such as chemotherapy [50]. T cells are engineered to express a tumour antigen by 
the integration of genes encoding conventional T-cell receptors (TCRs) or chimeric antigen 
receptors (CARs, receptors which may undertake MHC-independent targeting and thus 
combine the targeting specificity of antibodies and the cytotoxicity of T cells) [50, 51] (Fig 
3C). One of the most attractive CAR T cell applications is targeting overexpressed 
mesothelin in solid tumours, including mesothelioma [34]. It has been shown that adoptive 
transfer of engineered antimesothelin human CAR T cells regressed large human MPM 
xenograft tumors in immunodeficient mice in preclinical models [52]. Alternatively, CAR T 
cells were used to target non-transformed stromal cells, which promote cancer. CAR T cells 
were directed against fibroblast activation protein (FAP), which is overexpressed on the 
surface of reactive tumor-associated fibroblasts [53]. High level of FAP expression in tumour 
tissue of MPM patients has been reported highlighting the potential of using adoptive T-cell 
therapy as an effective approach to treat MPM [53]. 
 
2.1.11 Phase I Clinical Trials 
 
A clinical trial of CAR T Cell targeting mesothelin is recruiting participants who are 
diagnosed with metastatic cancers, including mesothelioma. The purpose of this study is to 
evaluate the safe number of enhanced T cells to infuse and effective doses in an estimated 
number of 136 subjects (NCT01583686). Another recruiting clinical trial aims to use 
redirected T cells against FAP to assess the safety of a fixed single dose by direct injection in 
the pleural effusion for patients (estimated number of six) with MPM not eligible for surgery 
(NCT01722149).  
 
 
2.1.12 Immune Checkpoint Treatment  
 
 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4; CD152) receptor and programmed death-
1/programmed death ligand-1 (PD1/PDL-1) are the major immune checkpoints targeted for 
clinical studies [54, 55] (Fig 3D). The biological role of immune checkpoints is to negatively 
regulate the immune response by downregulating T-cell function resulting in immune 
tolerance to self-antigens, and balancing the immune response [56, 57]_ENREF_9. CTLA-4 
exerts its inhibitory signal through competition with its positive counterpart, CD28, for its 
ligand B7 [57]. Preclinical studies reported that CTLA-4-deficient mice die due to lethal 
lymphoproliferation [58]. A strong preclinical rationale justified the development of two 
main immune checkpoint blockers: ipilimumab (known as MDX-010 or BMS-734016; 
Yervoy™, Bristol-Myers Squibb, Princeton, NJ), a fully human, IgG1 monoclonal antibody 
(mAb) which binds CTLA-4. Ipilimumab was the first immune checkpoint blockage therapy 
approved for treatment of metastatic melanoma in 2011 [59]. Ipilimumab was also approved 
by the Food and Drug Administration (FDA) as adjuvant for stage III melanoma [59].  
Tremelimumab (CP-675 206 or ticilimumab; Pfizer Inc, New York, NY, USA) is a 
humanized IgG2 mAb against CTLA-4 that has also been used in clinical trials, detailed 
below [60]. 
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Following the promising results of CTLA-4 blockage, other immune checkpoints such as the 
PD-1/PD-L1 pathway have been targeted. PD-1 is a negative regulator of T-cells since by 
interacting with the PD-L1 and the PD-L2 ligands limits their activity. Several therapeutic 
agents have been developed against PD-1 and PD-L1 but the development of autoimmune 
diseases has been observed in PD-1–deficient mice in preclinical studies [61]. Nivolumab 
known also as MDX-1106, BMS-936558, and ONO-4538; Opdivo®, Bristol-Myers Squibb, 
Princeton, NJ) is a humanized IgG4 mAb. Nivolumab has been approved by FDA for the 
treatment of Hodgkin lymphoma [62]_ENREF_51, unresectable or metastatic melanoma [63] 
and metastatic NSCLC [64]. Another therapy targeting PD-1 which has been clinically tested 
is pembrolizumab (MK-3475, lambrolizumab; Keytruda®, Merck, Whitehouse Station, NJ) 
which is an IgG4 engineered humanized Ab, approved in 2014 for the treatment of metastatic 
melanoma [65] and in 2015 for NSCLC [66]. 
Other drugs targeting PD-L1 such as atezolizumab (MPDL3280A; Tecentriq®, Genentech, 
Inc, South San Francisco, CA), an IgG1 humanized, engineered mAb, has also been 
developed. In October 2016 the FDA approved atezolizumab for NSCLC. Avelumab 
(MSB0010718C,EMD Serono, Rockland, MA)  is a fully human  IgG1 monoclonal PD-L1 
antibody. 
Recently, another component of the B7 family, called B7-H3 (CD276), has been shown to 
regulate the immune response being involved in the inhibition of the signalling of the T-reg 
cells. B7-H3 is over-expressed in a wide variety of solid tumour types [67]. Enoblituzumab 
(MGA271,) is an Fc-optimized humanized IgG1 mAb that binds to B7-H3 and has also been 
used in clinical trials, detailed in subsequent sections. B7-H3 is a negative immune 
checkpoint and it has been shown that its blockage can promote an anti-tumour immune 
response [68] 
All of these immune checkpoint blockage therapies have been or are under investigation in 
MPM in phase I or phase II studies as described below.  
 
2.1.13 Phase I  
 
Several phase I clinical trials have been designed to evaluate pembrolizumab in combination 
with standard chemotherapy, radiotherapy (NCT02959463) or novel strategies such as 
defactinib (a focal adhesion kinase (FAK) inhibitor) (NCT02419495 and NCT02758587). 
Some of them are currently recruiting and the main aim is to evaluate the safety of the 
combination of pembrolizumab in combination with standard chemotherapy (NCT02707666) 
in particular as a window of opportunity pilot trial of pembrolizumab in patients affected by 
resectable malignant pleural mesothelioma. One study is investigating the combination of 
pembrolizumab with an antiangiogenesis agent (nintedanib) since antiangiogenic therapy 
may synergize with immunotherapy, thus offering a benefit for the quality of life of patients 
with advanced solid tumours, including MPM (NCT02856425). First considerations about the 
clinical profile of pembrolizumab has been presented at the AACR Annual Meeting 2015 
with a phase Ib study (KEYNOTE-028: NCT02054806) showing safety, tolerance, and 
robust antitumor responses in patients with malignant pleural mesothelioma.  
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The PD-L1 inhibitor avelumab is under investigation in a phase I study that is currently 
recruiting patients with solid tumours including malignant mesothelioma (JAVELIN Solid 
Tumor: NCT01772004). Investigational studies of combined immunotherapy approaches are 
currently recruiting patients and are a phase I study of a combination modality of ipilimumab 
with enoblituzumab in refractory cancers, including MM (NCT02381314). Another phase I 
study evaluates the safety of enoblituzumab in combination with pembrolizumab in refractory 
cancers such as malignant mesothelioma (NCT02475213). 
 
2.1.14 Phase II Clinical Trials  
 
The success of ipilimumab and its approval for the treatment of metastatic melanoma, plus 
the promising clinical efficacy of immunotherapy in combination with other treatments, has 
led to the investigation of ipilimumab in two phase II studies in combination with nivolumab 
(NCT03048474 and NCT02716272). The combination treatment with two different immune 
checkpoint inhibitors may delay tumour progression in patients with unresectable malignant 
pleural mesothelioma. However, the central immune checkpoint tested in mesothelioma is 
tremelimumab which has been investigated mainly as single dose in three phase II studies. A 
phase II study of tremelimumab in patients with chemotherapy-resistant advanced malignant 
mesothelioma (NCT01649024) has been carried out. Tremelimumab showed an adequate 
safety and tolerability profile although only 29 patients were enrolled and no patients 
achieved  a complete response and only two patients (7%) exhibited a durable partial 
response (one of 6 months and one of 18 months) [69]. Another phase II trial assessed the 
efficacy and safety of an intensified schedule of tremelimumab in patients with unresectable 
advanced malignant mesothelioma (NCT01655888). In this study, 3% (one patient) achieved 
a partial response and 38% (11 patients) achieved disease control rate. Gastrointestinal and 
dermatological effects, as well as fever, were the major adverse effects observed that were 
related to treatment [70]. The results showed a well-tolerated and safe profile that led to the 
use of the same intensified schedule in an ongoing randomised, double-blind, placebo-
controlled, phase 2b study (NCT01843374). Tremelimumab has been selected for a combined 
therapy with another immune checkpoint targeting PD-L1 (MEDI4736). Two clinical studies 
are currently recruiting participants (NCT02588131 and NCT02592551). Nivolumab is also 
under investigation  in an ongoing phase II study as monotherapy in patients previously 
treated with chemotherapy with mesothelioma (NCT02497508). Recent recruiting clinical 
studies evaluate the activity of pembrolizumab as a monotherapy in malignant mesothelioma 
(NCT02399371 and NCT02628067) or in combination with cisplatin/pemetrexed 
(NCT02784171). Atezolizumab is under assessment in a recruiting phase II study in 
advanced solid tumours, including mesothelioma (NCT02458638).  
 
Table 2: Phase I and phase II clinical trials for different immunotherapeutic approaches. 
 
ClinicalTrials.gov 
Identifier 
Phase Treatment 
Number of 
Patients 
14 
 
NCT00066651 I 
SS1(dsFv)-PE38 
immunotoxin 
24 
NCT01445392 I 
SS1(dsFv)-PE38 in 
addition to cisplatin 
and pemetrexed 
24 
NCT00325494 I Amatuximab 24 
NCT01018784 1 Amatuximab 17 
NCT00003263 I 
INF-α combined with 
chemotherapy, 
radiotherapy and 
surgery 
6 
NCT00738582 II Amatuximab 89 
NCT01112293 II GC1008 (anti-TGF) 14 
NCT01583686 I/II 
Anti-mesothelin CAR 
T cells 
Currently 
recruiting 
NCT01722149 I 
Redirected anti-FAP 
T cells 
Currently 
recruiting 
NCT02959463 I 
Adjuvant 
pembrolizumab after 
radiation therapy 
Not yet recruiting 
NCT02419495 I 
Numerous (including 
pembrolizumab and 
selinexor) 
142 
NCT02758587 I/II 
Defactinib and 
pembrolizumab 
Not yet recruiting 
NCT02707666 I 
Pembrolizumab in 
combination with 
cisplatin and 
pemetrexed 
Currently 
recruiting 
NCT02856425 I 
Nintedanib and 
pembrolizumab 
Currently 
recruiting 
NCT02054806 I Pembrolizumab 477 
NCT01772004 I Avelumab 
Currently 
recruiting 
NCT02381314 I 
Enoblituzumab in 
combination with 
ipilimumab 
Currently 
recruiting 
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NCT02475213 I 
Enoblituzumab in 
combination with 
pembrolizumab 
Currently 
recruiting 
NCT03048474 II 
Nivolumab and 
ipilimumab 
Currently 
recruiting 
NCT02716272 II 
Nivolumab 
monotherapy or 
nivolumab in 
conjunction with 
ipilimumab 
125 
NCT01649024 II Tremelimumab 29 
NCT01655888 II Tremelimumab 29 
NCT01843374 II Tremelimumab 658 
NCT02588131 II 
Tremelimumab in 
combination with 
MEDI4736 (anti-PD-
L1) 
Currently 
recruiting 
NCT02592551 II 
MEDI4736 or 
MEDI4736 in 
combination with 
tremelimumab 
Currently 
recruiting 
NCT02497508 II Nivolumab 33 
NCT02399371 II Pembrolizumab 
Currently 
recruiting 
NCT02628067 II Pembrolizumab 
Currently 
recruiting 
NCT02784171 II 
Pembrolizumab, 
cisplatin, pemetrexed 
Currently 
recruiting 
NCT02458638 II Atezolizumab 
Currently 
recruiting 
 
 
2.2 Multiple Targeted Therapies: Small Molecule and Antibody Approaches  
 
The increased understanding of molecular pathways involved in tumorigenesis allows for the 
development of valid rationales to specifically target malignant cells in solid tumours, 
including MPM. It is well-known that proliferative signalling promotes tumour progression by 
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releasing growth factors such as epidermal growth factor receptor (EGFR) which plays a 
pivotal role in proliferation and mediates cell growth by activating specific downstream 
pathways contributing to survival, differentiation, migration and adhesion. EGFR is part of the 
family of transmembrane tyrosine kinase receptors (TKRs), including platelet-derived growth 
factor receptors (PDGRs), fibroblast growth factor receptors (FGFRs) and vascular endothelial 
growth factor receptors (VEGFRs) [71]. The discovery of the role of this family prompted the 
development of tyrosine-kinase inhibitors (TKIs), small molecules able to target the 
intracellular tyrosine kinase residue such as gefitinib and erlotinib which target EGFR (Fig 4). 
In MPM, studies revealed that EGFR was overexpressed at the protein level in around 52% of 
MPM patients [72, 73, 74]_ENREF_62. The role of vascular endothelial growth factor (VEGF) 
and its receptor VEGFR has been identified in MPM, showing high levels of both molecules 
in tissue specimens [75]. Numerous inhibitors have been designed and tested in MM for these 
targets such as vatalanib, sorafenib, nintedanib, axitinib and cediranib and have shown limited 
or absent levels of activity, resulting in a lack of clinical benefits [76, 77]. The most promising 
treatment to interact with VEFG signalling is bevacizumab (Avastin), a humanized 
monoclonal antibody against VEGFA which was approved in the EU in 2005 for the treatment 
of many solid cancers such as NSCLC, colorectal carcinoma, renal cell, and ovarian [78, 79, 
80, 81] (Fig 4).  
Moreover several small molecules acting as inhibitors have been developed for different 
pathways, including against targets involved in epigenetic regulation of tumour suppressor 
genes, such as histone deacetylase (HDAC) inhibitors. The main agents tested in clinical trials 
are belinostat and vorinostat. Another strategy uses asparagine–glycine–arginine–human 
tumour necrosis factor α (NGR-hTNF) which is TNF-alpha fused with NGR. NGR is able to 
bind specifically an aminopeptidase N isoform overexpressed on tumour blood system [82, 
83] . FAK represents an encouraging target for MPM in particular due to its  involvement in 
cancer stem cell (CSC) renewal [84]. Recently reported targeted therapies include RNA as a 
therapeutic target using ranpirnase, which promotes  impaired protein synthesis and cell cycle 
arrest, leading to an antitumor activity [85].  Moreover, it is possible to list a variety of 
inhibitors for example; heat shock protein 90 (HSP90) inhibitor (ganetespib), enhancer of 
zeste homolog 2 (EZH2) inhibitor (tazemetostat), inhibitor of the MET receptor tyrosine 
kinase (tivantinib), CSC inhibitor (napabucasin/BBI608) and TargomiRs (a mimic microRNA 
treatment).  
  
2.2.1 Phase I Clinical Trials 
 
A phase I study investigated the clinical profile of vorinostat in advanced tumours, including 
13 patients with MPM [86]. The results of this study demonstrated there was no improved 
survival with the use of this drug.  Although vorinostat has been tested in a phase III study as 
a second-line therapy, there was no improvement in OS and it cannot be suggested as an 
option for treatment for MPM patients in advanced stage [87]. 
 
2.2.2 Phase II Clinical Trials 
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Gefinitib (ZD1839, Iressa) is the main TKI studied in a clinical trial involving 40 malignant 
mesothelioma patients with unresectable disease but did not show any clinical benefit despite 
the fact that 97% of patients overexpressed EGFR (NCT00025207) [88]. Erlotinib, another 
TKI, did not improve survival in a study when used as a single agent in untreated patients 
[89].  Promising results have been reported from a study of erlotinib in combination with 
bevacizumab in pre-treated patients, showing a stable disease in 50% of patients, a PFS of 2.2 
months and a median survival of 5.8 months (NCT00137826) [90]. Bevacizumab, one of the 
most promising anti-VEGF therapeutic agents, has been tested in combination with cisplatin 
plus gemcitabine in a multicentre study involving 108 chemo-naïve mesothelioma patients. 
PFS was 6.9 months for the bevacizumab arm versus 6 months for the placebo and OS was 
improved by only 1 month (15.6mo vs 14.7mo) (NCT00027703). From these data, the 
conclusion is that bevacizumab does not improve PFS and OS [91]. However, an additional 
phase III study showed that bevacizumab in combination with pemetrexed and cisplatin 
improved overall survival by 2.7 months relative to pemetrexed and cisplatin alone [92]. A 
study of belinostat has been performed in patients with relapsed MPM but did not show 
activity in patients (NCT00365053) [93]. Defactinib (VS-6063) is a potent selective FAK 
inhibitor. A phase II randomized multicenter trial (COMMAND) of defactinib in previously 
treated MPM was initiated but the study has been terminated due to the lack of evidence that 
it is efficient (NCT01870609). 
 
 
2.3   Gene Therapy 
 
Another therapeutic approach under investigation for MPM is gene therapy which consists of 
the transfer of genetic material in cells for therapeutic purposes. In MPM, several genes have 
been detected to be interesting targets for gene therapy and different types of delivery 
systems have been clinically investigated to assess safety and activity in MPM patients [94]. 
MPM represents a promising target for gene therapy since the MPM tumour lining to the 
pleural cavity makes it easy to reach using in vivo gene delivery [95]. Although these trials 
have demonstrated good safety results, there has been relatively limited efficacy [96]. 
 
2.3.1 Suicide Gene Therapy 
 
Suicide gene therapy uses viruses to deliver a transgene which encode for a specific enzyme 
that is able to transform a prodrug  into toxic metabolites, leading to tumour cell death or 
“suicide” [97]. The most commonly investigated  approach is herpes simplex virus-1 
thymidine kinase (HSVtk) gene which sensitises transduced cells to the nucleoside nontoxic 
antiviral drug ganciclovir [94] (Fig 5A). 
 
2.3.2 Cytokine Gene Therapy 
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Cytokine gene therapy is a promising treatment since it has the ability to activate systemic, 
intrapleural, and intratumoral immune effector cells. Cytokine gene therapy is an improved 
technique to express increased amount of cytokines (such as IL-2, IL-12, TNF or INF -α, β, 
or γ) using a viral vector with the advantage to reduce toxicity and increase the local 
concentration [98] (Fig 5B). 
 
2.3.3 Phase I Clinical Trials 
 
Clinical trials assessing gene therapy for mesothelioma have been designed. One study tested 
transgene expression and clinical profiles in MPM patients receiving high-dose adenovirus 
HSVtk/ganciclovir suicide gene therapy [99]. The intrapleural administration was safe and 
well-tolerated in 34 patients but in only 2 long-term durable responses to the treatment were 
evident. Another study assessed  the gene transfer,  immune response profile and tumour 
response of single-dose intrapleural IFN-β gene transfer using an adenoviral vector (Ad.IFN-
β) in 10 mesothelioma patients, the results of which showed immune responses at a high rate 
[100]. A clinical trial testing adenoviral-mediated IFN-β gene as a monotherapy for MPM 
patients is ongoing (NCT00299962). The first one is investigating two doses of the treatment 
whilst the second is a dose-escalation study. Currently an ongoing study “Autologous 
Redirected RNA Meso-CIR T Cells” is evaluating the safety and potential of Meso-CIR T 
cells (autologous chimeric immune receptor T cells that have been transfected with an anti-
mesothelin mRNA) in 18 patients (NCT01355965). 
 
Table 3: Phase I and II clinical trials for targeted and gene therapies. 
 
ClinicalTrials.gov 
Identifier 
Phase Treatment 
Number of 
Patients 
NCT00025207 II 
Gefitinib (EGFR 
inhibitor) 
40 
NCT00137826 II 
Bevacizumab (VEGF 
inhibitor) and 
erlotinib (EGFR 
inhibitor) 
37 
NCT00027703 II 
Chemotherapy with or 
without bevacizumab 
106 
NCT00365053 II 
Belinostat (HDAC 
inhibitor) 
13 
NCT01870609 II 
Defactinib (FAK 
inhibitor) 
344 
NCT00299962 I Adenoviral-mediated 18 (estimated, 
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IFNβ study ongoing) 
NCT01355965 I 
Redirected RNA 
Meso-CIR 
Autologous T Cells 
18 
 
 
3. Expert Opinion  
There is no doubt that in the last few years more effort has been placed in developing and 
testing new therapeutic options for mesothelioma. Unfortunately the major weakness of this 
(welcome) interest has been the idea that therapies with some activity for other tumours could 
be applied “tout court” to mesothelioma. It is clear that this approach is not based on a solid 
scientific background and is unlikely to achieve significant results. 
Among others factors, it is our opinion that taking the hypoxic microenvironment of 
mesothelioma into account can assist in the development of much more “mesothelioma 
tailored” therapies [101]. With regard to what the clinical trials for mesothelioma so far have 
shown as  the “best result” underpinning the front line therapy for this neoplasm is based on a 
trial that allows a gain of survival of 2.7 months and  on a preclinical  study published by our 
group sixteen years ago [92, 102]. 
Hence rather than discussing what the most promising results of treatment for this tumour 
have been so far we should ask ourselves why we have not achieved more significant steps 
forward yet. In our understanding a more precise focus on mesothelioma biology 
(encompassing genetics, metabolomics and functional studies) conducted on cell models 
closer to the in vivo events in primary tumour cell lines and 3D studies could foster our 
clinical impact. It is clear that surrogate end points such as progression-free survival do not 
mirror the real clinical effect of any novel treatment in oncology [103]. As opposite our 
purpose should be that of extending mesothelioma patient survival by longer than three 
months. 
This is particularly true for immunotherapy as recently demonstrated by the failure of clinical 
trials for mesothelioma with OS as a primary end point (in spite of some efficacy of the phase 
II trials) and, more generally, by the low number of patients who can truly benefit from 
immune checkpoint inhibitors. Moreover, the purely “genetic” approach to cancer treatment 
is currently being discussed and evaluated. This approach is even more contentious when one 
looks at the low mutational load of MPM [103, 104]. 
 
We believe that only a more integrated and balanced approach to MPM will allow us to get 
ahead and achieve more significant clinical results. This should encompass multiple 
disciplines such as genetics, biochemistry and immunology that are already applied to cancer 
research and be even more focused on MPM than done so far. A more precise understanding 
of how the stroma may affect the response to therapy is also an important area and offers a 
novel therapeutic target [53, 105]. The effect of microenvironment and the subsequent MPM 
metabolic reprogramming offers a unique scenario with potentially significant therapeutic 
implications for this orphan disease (manuscript in preparation). 
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Ultimately magic bullets do not exist in oncology but we are confident that an unbiased 
multidisciplinary approach to this tumour could allow us to achieve significant results sooner 
than expected. Metabolic reprogramming of tumour cells, the hypoxic microenvironment and 
the stroma are all areas that offer promising points of interest for therapeutic development. 
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Figure 1. Passive Immunotherapy: Dendritic cell-based vaccines are developed by isolating 
immature dendritic cells from the patient and incubating them ex- vivo with tumour lysate. 
Mature DCs are injected back to the same patient to induce a tumour-specific immune 
response by activating tumour-specific CD8+ T cells. 
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Figure 2. Peptide-based vaccines are single peptides or a cocktail of peptides obtained from 
cancer cells of patients and are amplified ex-vivo. These peptides are conjugated to an 
adjuvant and are injected back to the patient. DCs endocytose these peptides and present 
them and activate CD4+ cells which subsequently induce CD8+ CTL specific anti-tumour 
immune response. 
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Figure 3. Schematic representation of passive immunotherapeutic strategies. A) antibody-
based strategy using monoclonal antibodies or immunotoxins against cancer cells (mesothelin 
is the main target for mesothelioma). B) Cytokine-based therapy provides cytotoxic immune 
response by activating natural killer (NK) cells or tumour-specific cytotoxic T cells. C) 
Adoptive T cells therapy uses engineered T cells expressing T-cell receptor (TCR) or a 
chimeric antigen receptor (CAR) to interact with cancer cells; D) In immune checkpoint 
blockade approach monoclonal antibodies specifically recognizing receptors such as the 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor or the programmed death-
1/programmed death ligand-1 (PD1/PDL-1) are used to block the function of these receptors. 
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Figure 4. Graphic representation of anticancer multiple targeted approaches in MM. 
Belinostat and vorinostat induce DNA damage whereas the antibodies bevacizumab, gefitinib 
and erlotinib prevent the binding of VEGF and EGF respectively to their receptors thereby 
inhibiting their intracellular signalling. Bevacizumab functions extracellularly whereas the 
small molecules sorafenib and vatalanib inhibit the VEGFR intracellular signalling. 
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Figure 5. Summary of gene therapies for MM treatment. A) Suicide gene therapy: tumour 
cells modified to express a specific enzyme to metabolise a prodrug into a cytotoxic product 
to induce tumour cell death; B) Cytokine gene therapy: expression of cytokines to activate a 
more effective immune response. 
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